The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Open accessPublished version of a preprint
Abstract
Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results of phase 1 study demonstrated CAR-T cell therapy combined with α-PD-1/PD-L1 had confirmed antitumor activity in patients with malignant pleural diseases [344].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [344]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citationInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062
Self-citationZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Self-citationCombination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Self-citation
Cited by
Sorted by citations
Items 501–599 of 599
Cheng, Y., Lin, D., Yu, S., Liu, X., Yan, C., & Cheng, W. (2023) · Research Square · doi:10.21203/rs.3.rs-3326672/v1
Einsatz von T-Zelltherapien in der soliden Onkologie
Müller, P. J., & Kobold, S. (2023) · BIOspektrum · doi:10.1007/s12268-023-2042-4
Towards inmunotherapeutic exploitation strategies of rotumor and antitumor cytokines
Olivera, I. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/69099
Kamala, K., Ganapathy, D. M., & Sivaperumal, P. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100347
Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial
Zauderer, M. G., & Dagogo‐Jack, I. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00291-2
Self-citationChallenges and Feasible Solutions of CART Therapy in Solid Tumors
Wang, Z. (2024) · MedScien · doi:10.61173/db2q9t74
New Treatment for Pleural Mesothelioma
Fujimoto, N. (2024) · Haigan · doi:10.2482/haigan.64.269
Les cellules CAR-T anti-CD19 : prototypes du médicament vivant
Sadelain, M., & Rivière, I. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.10.009
Self-citationPrise en charge diagnostique et thérapeutique du mésothéliome pleural en 2024
Scherpereel, A., Vénissac, N., Humez, S., Ulmer, L., Locatelli-Sanchez, M., Brosseau, S., Dhalluin, X., Nunes, D., Gounant, V., Lantuéjoul, S., et al. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00093-4
Commentary: Blood biomarkers: Barriers and benefits
Bellis, R. Y., Cranwell, V. N., & Adusumilli, P. S. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.10.040
Self-citationCluster of Differentiation 155 Expression in Early-Stage Lung Adenocarcinoma
Cranwell, V. N., & Adusumilli, P. S. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.07.011
Self-citationPaired CRISPR screens to map gene regulation in cis and transPreprint
Xue, X., Gajic, Z. Z., Caragine, C. M., Legut, M., Walker, C. R., Kim, J. Y. S., Wang, X., Yan, R., Wessels, H., Lu, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625752
Self-citation贾, 书. (2025) · World Journal of Cancer Research · doi:10.12677/wjcr.2025.151004
Combination of CAR T cell therapies with immune checkpoint inhibitors
Lin, H. K., Blake, D. A., & Rafiq, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00040-0
T Cell Therapies (TIL, CAR T, TCR)
Julve, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00144-7
(2025) · Acta Scientific Medical Sciences · doi:10.31080/asms.2025.09.2068
Charkhchi, P., Le, R., Cazzolli, T. E., Flores, R. R., Martinez, R. A., Kaur, S., & Kitano, M. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2535941
Pavlisko, E. N., Li, H., Piña‐Oviedo, S., Nel, A. E., Glass, C., & Sporn, T. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-89250-9_5
Novel Immune Modulatory Agents in the Treatment of Non-small Cell Lung Cancer
Reyes, A., & Lee, M. (2025) · Cancer treatment and research · doi:10.1007/978-3-031-97242-3_8
Commercialization of nanoimmunoengineering
Hussain, A., & Webster, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21521-6.00012-0
Mésothéliome pleural : algorithme thérapeutique
Locatelli-Sanchez, M., Scherpereel, A., Vénissac, N., Humez, S., Ulmer, L., Brosseau, S., Dhalluin, X., Nunes, D., Gounant, V., Lantuéjoul, S., et al. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00084-9
Immunotherapy for breast cancer
Chaturvedi, A., & Shukla, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33349-1.00001-6
Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines
Panou, V., Sørensen, J. B., Ravn, J. B., & Santoni‐Rugiu, E. (2025) · European Clinical Respiratory Journal · doi:10.1080/20018525.2025.2580795
Cheng, C., Zhang, L., Cao, J., Li, X., Wen, Y., Liu, K., & Zhao, T. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf035
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Lang, B., Wang, M., Zhang, Z., Fu, Y., Han, X., Hu, Q., Ding, H., Shang, H., & Jiang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24709062
Advances in PD-1/PD-L1 inhibitor combinations with standard therapies for hematological malignancies
Zeng, Y., He, G., Zhang, Z., & Zhu, M. (2025) · Academia oncology. · doi:10.20935/acadonco8033
T-Cell Receptor Engineered T-Cell Therapy
Leibou, S., Dinerman, A. J., & Klemen, N. D. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.12.001
CAR T-Cell Therapy for Solid Tumors
Gutierrez, A., & Eil, R. L. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.001
Harnessing hemostasis to transform surgical scars into CAR-T immunological niches
Cheng, X., & Cheng, K. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535463123
Immunotherapy resistance and strategies in malignant pleural mesothelioma
Xia, W., Li, S., Zeng, Q., Zhang, Y., 赵娟芝, Tan, X., Ju, S., Zou, W., Chen, C., Li, C., et al. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2025.215
Zhang, L., Zhang, Q., Zhang, X., Mao, A., Liu, Y., & Luo, H. (2026) · MedComm – Future Medicine · doi:10.1002/mef2.70051
Li, D. D., Gu, X., Li, J., Huang, Y., Zhou, W.-L., Li, J., Wang, F., Yan, F., Gao, H., Ying, X., et al. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01025-8
Efficacy and synergy of low-dose radiotherapy combined with anti-PD-L1 based immunotherapy
Laurent, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/e7695737z26a3z4747zafafzb19e3e74372b
Park, M.-S., Gunassekaran, G. R., Lee, S.-M., Vadevoo, S. M. P., Jo, D. G., Kim, S., Ha, E., Kim, S.-K., Ahn, H., Chung, S.-J., et al. (2026) · Biomaterials Research · doi:10.34133/bmr.0361
Yerigeri, K., Sengupta, M., Zhang, J., Puthiamadathil, J., & Hassan, R. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.04.005
Cancer Immunotherapy Using Immune Checkpoint Blockade
Tayebi, L., & Abdolmaleki, M. (2026) · Springer eBooks · doi:10.1007/978-981-95-8026-2_5
Update on pleural mesothelioma
Tan, D. J. H., Chin, W. L., & Lee, G. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001272
Directing mesothelin-targeted chimeric antigen receptor T cells to solid tumors
Cranwell, V. N., Rubino, V., & Adusumilli, P. S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.002
Self-citationHe, L., Sun, Y., Ma, B., Lang, G., Wen, J., Blumenschein, G. B., & Ma, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772428
Role of CD4+ T-cells in cancer immunology
Rajput, M. S., Saxena, B., Gupta, R., Mandlik, D., & Natesan, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00011-4
Role of adoptive cell therapy in cancer immunotherapy
Puri, G., Singh, B. K., & Ranjan, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00004-7
IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity
Huang, Y., Liu, X., Chen, Y., Zhang, H., Zhang, J., Fu, Y., Yang, X., & Yang, Z. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218563
Rapidly evolved PD-1 for enhance receptor and checkpoint inhibitor in immunotherapy
Mei, X., Li, X., Wu, Y., Fu, D., Zhang, F., Yan, T., Gu, W., & Gao, B. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201228
Hou, X., Yang, L., Liu, F., Wang, F., Liu, S., Yao, Y., Wang, Z., Qi, C., Zhu, H., & Yang, Z. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00244
Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies
Volpe, A., Zurita, J., Shenker, L., Mane, M. M., Adusumilli, P. S., Aleshin, A. E., Rozanov, D. V., & Ponomarev, V. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014330 · Cited by 1
Self-citationSpatial Omics Revisits Cancer Immunity and Reshapes Immunotherapy
Chu, H., Shi, Y., Tian, Z., Ma, J. Y., Bian, X. W., & ZHU, B. (2026) · Fundamental Research · doi:10.1016/j.fmre.2026.04.033
Oh, N., & Trinh, V. N. (2026) · Cells · doi:10.3390/cells15100910
Evaluating mesothelin as an immunotherapeutic target for endogenous T cells
Koukoulias, K., Yanagisawa, R., Chavez, A. G. T., Papayanni, P. G., Velazquez, Y., Lee, H., Vasileiou, S., & Leen, A. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1853409
Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption
Liu, Z., Cai, Z., Zhang, J., Yu, X., & Yang, X. (2026) · Medical Review · doi:10.1515/mr-2026-0017
Reversible control of CAR T cells through PROTAC compound targeting bromodomain mutant
Kim, Y., Lee, D. Y., Choi, J. U., Jeun, M., Lee, H. K., Choi, S. U., & Park, C. H. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201280
Tuning the tumor, trafficking the T cell: sIRE opens the door for solid tumor CAR T cells
Banerjee, S., Jalan, P., Erkhem‐Ochir, B., Srimathveeravalli, G., & Adusumilli, P. S. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201275
Self-citationEl‐Sehrawy, A. A. M. A., Alfreahat, I., Bobokulov, N., o‘gli, T. Q. N., Shakhmurova, G., Panigrahi, R., Hashem, R. M., & Bainsal, N. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70252
CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers
Aghayan, S. K., Azizan, A., Ghaleh, H. E. G., Salimi-Sabour, E., Mirnejad, R., Vazifedust, S., Abyazi, M. A., & Nazarpour, V. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119697
HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap
Pedregal, M., & Moreno, V. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.06.018
Immunocompromised Patients and Oncologic Complications
Kumar, S., Balabayova, K., & Pastores, S. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_35
Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies
Sha, S., Pang, X.-Y., Wang, N., Wang, Y., Zhang, C., Guo, Z., Du, Z., Li, L., Liu, N., & Qu, L. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101452
Lin, H. K., Blake, D. A., Freeman, R., Chen, Y. H., Kim, J., Johnson, A. M., Wells, K., Mudigonda, A., Liu, W., Yadav, P., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adt9565
Wagner, P. L., Lewis, C., Mirsky, P. O., Kucherenko, O. O., Sherry, C., Szeligo, B. M., Altpeter, S., Devine, S., Donnenberg, V. S., Dadgar, N., et al. (2026) · Surgical Oncology Insight · doi:10.1016/j.soi.2026.100277
Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy
Wu, B., Wang, J., Zou, Q., Cai, J., Zhang, Y., Zhong, Q., Bai, B., Liu, F., Cao, Y., Li, P., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00974-4
Optimal transport analysis of high-dimensional flow cytometry data in immuno-oncology
Shemonti, A. S., Wang, J. C., Donnenberg, A. D., Rajwa, B., Wagner, P. L., Bartlett, D. L., Popov, B., Alicuben, E. T., & Donnenberg, V. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1856896
Kanjani, V. G., Bharadia, A. A., & Morakhia, K. R. (2026) · Regenerative medicine reports . · doi:10.4103/regenmed.regenmed-d-26-00003
Onyekweli, S. O., Omoruyi, G. O., Akintayo, C. O., & Olaniyi, K. S. (2026) · Oncoscience · doi:10.18632/oncoscience.666
Kong, Z., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891408
Wang, X., Wang, Q., (2085), W. G., He, S., Xiong, D., Huang, Y., & Zou, B. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02748-w
Self-citationCAR-T in solid tumors: Obstacles and potential strategies
Ding, Z., Li, Y., & Huang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.047
Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine
Bailey, C. A., Cui, Y. X., Marjon, N. A., Bitler, B. G., & Shields, C. W. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100550
Exploiting Tumor-Targeted Drug Delivery Strategies
Kumar, A., Tuteja, D., Yadav, A. K., Borasi, H., & Bhatia, D. D. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_16
He, F., Zhu, X., Wang, X., Ju, X., Wu, F., Di, W., Su, S., & Huang, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108368
Self-citationReprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance
Cheng, W., Liu, M., Diao, Y.-H., Chen, B., Wen, Y.-P., Zhang, C., Liu, M.-T., Shao, Z.-Q., Cai, J.-Y., & Cao, B. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i3.47
Li, H., Zhou, K., Xu, R., Wang, W., Song, T., Zhou, Y., Ren, J., Wang, Z., Liang, Y., Chen, Y., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1883870
Zelluläre Therapien in der Lungenmedizin: Neue Perspektiven bei Infektionskrankheiten und Tumoren
Jantz-Naeem, N., Hasdorf, J., Proemmel, M., Mougiakakos, D., Kahlfuss, S., & Fricke, S. (2026) · Deutsches Ärzteblatt Online · doi:10.3238/perspneumo.2026.08.21.02
CAR-T CELL THERAPY IN ONCOLOGY AND RHEUMATOLOGY
Tyczka, K., Szczepanik, M., Nowakowska, M. K., Senko, J., Kulpa, J., & Suchanek, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6385
In vivo CAR‑T therapy: recent progress and future directions
Wang, W., Cai, Y., Yang, X., & Xu, H. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00050-4
Zhang, Q., Qin, Z., & Guo, C. (2026) · MedComm – Oncology · doi:10.1002/mog2.70097
T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials
Zhao, J., Bangolo, A., Zhang, L., Gutierrez, M., & González-Vélez, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1917770
Adoptive cell therapy in lung cancer: progress, challenges, and prospects
Li, J., Tong, C., Chen, Y., & Zhu, B. (2026) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2026.08.002
Nezhad, M. S. H., Gol, S. Z., Gharavi, P., & Javid, H. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12720-y
Bao, Q.-H., Wu, A., Pang, J.-M., Wang, J.-W., Chen, Q., & Wu, S.-W. (2026) · Oncology Reviews · doi:10.3389/or.2026.1905358
Mast, A., Atar, D., Ruoff, L., Scheuermann, S., Kristmann, B., Lang, P., Seitz, C. M., & Schlegel, P. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2717853
Wang, K., Li, L., Yu, Z., Li, D., Jiang, J., Guo, Z., Wang, L., Zhang, H., Xu, L., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1957437
Bhattacharjee, A., Patil, V. M., Kothari, R., Patel, A., Jain, A., Parekh, D. S., Goyal, G., & Mahajan, M. U. (2026) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_30_26
From failure to fate: Pressure-driven exhaustion in solid-tumor CAR T-cell therapy
Wang, P., Zhou, Y., Wang, Y., Li, Y., Xiao, X., & Wang, C. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100377
Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers
Zeng, L., Wei, S., Chen, N., & Xie, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1942381
Qu, Q., Xiao, J., Zhao, B., & Gu, P. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101375
Niu, Q., Li, M., Zhang, C., Li, Q., Wang, M., & Liu, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1968080
Zhao, J., Zhang, Y., Wei, Z., Li, K., Li, D., & Wang, Y. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb01815g
Toward the next generation of CAR T cell therapies for cancer
Usta, D., & Mackall, C. L. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.005
Hu, J. (2026) · Theoretical and Natural Science · doi:10.54254/2753-8818/2027.mb38003
Vo, M.-C., Kim, S. K., Bae, W. K., Ruzimurodov, N., Jung, S.-H., & Lee, J.-J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1983828
Huang, P., Wu, W., Min, Y., Zhang, Y., Tao, Y., Liu, Z., Wei, Z., & Peng, X. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00848-3
Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
Bai, Y.-S., Qin, J.-T., Dai, Z.-J., Yan, R., Yang, Y., & Wang, W.-G. (2026) · Exploration · doi:10.1002/exp2.70230
Antigen-Guided Synthetic Receptor Engineering for Safer T Cell Immunotherapy in Solid Tumors
Kang, S., Cho, H. J., Kim, J.-H., & Lee, H. (2026) · Immune Network · doi:10.4110/in.2026.26.e40
Zhang, J.-M., Ma, X., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1987098
Heydari, F., Alqassimi, M. S., Mansuri, N., Derakhshani, M., Hamblin, M. R., & Naghinezhad, J. (2026) · Discover Nano · doi:10.1186/s11671-026-05095-3
Metadata
- Authors
- Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., Pineda, J., Perez-Johnston, R., Tan, K. S., Daly, B., Araujo Filho, J. A., Ngai, D., McGee, E., Vincent, A., Diamonte, C., Sauter, J. L., Modi, S., Sikder, D., Senechal, B., Wang, X., Travis, W. D., Gönen, M., Rudin, C. M., Brentjens, R. J., Jones, D. R., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 5Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Adusumilli, Prasad S.
- ORCID
- Adusumilli, Prasad S.
- Zauderer, Marjorie G.
- Rivière, Isabelle
- Solomon, Stephen B.
- Rusch, Valerie W.
- O'Cearbhaill, Roisin E.
- Cheema, Waseem
- Chintala, Navin K.
- Pineda, John
- Perez-Johnston, Rocio
- Tan, Kay See
- Daly, Bobby
- Sauter, Jennifer L.
- Modi, Shanu
- Wang, Xiuyan
- Travis, William D.
- Gönen, Mithat
- Rudin, Charles M.
- Brentjens, Renier J.
- Jones, David R.
- Sadelain, Michel
- Venue
- Cancer Discovery
- Published
- 2021-07-15
- Volume
- 11
- Issue
- 11
- Pages
- 2748-2763
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8563385
- OpenAlex
- W3179214161
- Cited by
- 605
- References
- 37
- Citations by year
- 2026: 124 · 2025: 119 · 2024: 131 · 2023: 125 · 2022: 90 · 2021: 15
- FWCI
- 32.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (P30 CA008748, R01 CA236615-01, R01 CA235667)
- U.S. Department of Defense (BC132124, LC160212, CA180889)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- mesothelin, chimeric antigen receptor T cells, CAR T-cell therapy, malignant pleural mesothelioma, malignant pleural effusion, pembrolizumab, anti-PD-1 therapy, intrapleural administration, combination immunotherapy, autologous T cells, safety and tolerability, overall survival
- MeSH terms
- Mesothelin, Humans, Mesothelioma, Pleural Diseases, Immunotherapy, Adoptive, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
